Sensei Biotherapeutics (SNSE)

• Market cap: $11M
• 1 day: -1.40%
• 5 days: -1.56%
• 1 month: -10.10%
• 3 months: -0.91%
• 6 months: -19.26%
• Year to date: -15.34%
• 1 year: -53.62%
• 5 years: -97.69%
• 10 years: -97.69%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.

Employees: 28

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

21% more funds holding

Funds holding: 19 [Q3] → 23 (+4) [Q4]

0.56% more ownership

Funds ownership: 8.78% [Q3] → 9.33% (+0.56%) [Q4]

13% less capital invested

Capital invested by funds: $1.32M [Q3] → $1.15M (-$170K) [Q4]

91% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 11

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 817% upside
• Avg. target: $4 817% upside
• High target: $4 817% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Edward White 28% 1-year accuracy 41 / 147 met price target

817% upside $4

Buy Reiterated

10 Jan 2025